BioVie financials
$1.540.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$22.7M | -$18.1M | -$32.2M | -$45.1M | -$27.3M | -$138.1M |
| Net income | -$22.1M | -$17.9M | -$33.0M | -$50.3M | -$26.1M | -$183.8M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-3.05 | $-12.12 | $-73.05 | $-154.70 | $-106.00 | $-1482.00 |
| EBITDA | -$22.5M | -$17.8M | -$32.0M | -$44.9M | -$27.0M | -$137.8M |
| Operating cash flow | -$19.0M | -$19.0M | -$27.9M | -$40.3M | -$19.0M | -$10.5M |
| Free cash flow | -$19.0M | -$19.0M | -$27.9M | -$40.3M | — | — |
| Diluted shares | 7.2M | 1.5M | 0.5M | 0.3M | 0.2M | 0.1M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.0M | $17.5M | $23.8M | $19.5M | $18.6M | $4.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $14.5M | $0.00 | — |
| Total debt | $0.00 | $0.00 | $5.7M | $14.3M | $12.1M | $0.00 |
| Total assets | $14.3M | $21.6M | $25.2M | $35.1M | $20.1M | $6.0M |
| Total liabilities | $4.0M | $2.6M | $9.7M | $19.8M | $16.4M | $996.4K |
| Shareholders' equity | $10.3M | $19.0M | $15.5M | $15.3M | $3.7M | $5.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology